MORRISTOWN, N.J., December 3, 2025
Further to the announcement made on September 23, 2025, Alvogen Pharma US, Inc. (“Alvogen”) today announced the successful completion of the sale of its parent company to Lotus Pharmaceutical Co., Ltd. (“Lotus”, TWSE: 1795), following receipt of all required regulatory approvals and satisfaction of customary closing conditions. Alvogen is now a controlled subsidiary of Lotus.
Advisors
Jefferies LLC and Rothschild & Co acted as joint financial advisors to Alvogen on this transaction, and White & Case LLP acted as legal advisor.
About Alvogen
Alvogen is a US company focused on developing, in-licensing, manufacturing and marketing pharmaceutical products. Alvogen is growing its portfolio of complex, high value products including inhalation, long acting injectables, peptides and strategic 505(b)(2) brand products. Presently, Alvogen has over 30 products currently on market and extensive R&D capabilities fueling its growing pipeline. Alvogen maintains a dedicated manufacturing facility in the United States, with significant capacity to expand. Alvogen is now a subsidiary of Lotus Pharmaceutical Co., Ltd., the international pharmaceutical company.
About Lotus
Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)(2), NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness.